Extracorporeal removal of LDL in the treatment of familial hypercholesterolemia

Экстракорпоральное удаление липопротеидов низкой плотности при лечении семейной гиперхолестеринемии
Abduzhappar Gaipov 1, Saule Abseitova 2, Dmitriy Malykh 3
More Detail
1 Department of extracorporeal blood correction, JSC “National Scientific Medical Center”, Astana, Kazakhstan
2 Department of Cardiology, JSC “National Scientific Medical Center”, Astana, Kazakhstan
3 Department of Internal Medicine, JSC “Astana Medical University”, Astana, Kazakhstan
J CLIN MED KAZ, Volume 2, Issue 36, pp. 15-22.
OPEN ACCESS 3477 Views 2584 Downloads
Download Full Text (PDF)

ABSTRACT

Familial hypercholesterolemia is inherited genetic disease characterized by high cholesterol levels in the blood and high risk of cardiovascular disease. There are mutations in the LDL-receptor gene, so the diseases have specifically high levels of low-density lipoproteins. Combination of non-drug therapies in with lipid-lowering drugs does not often reach to the steady normalization of the lipid profile. However, in Kazakhstan available method for extracorporeal removal of LDL is Heparin-induced Extracorporeal Lipoprotein Precipitation (HELP therapy). The main step of the process is selective precipitation of LDL with heparin, different values of pH and immunoadsorption membrane filtration. This mini review discussed diagnostic approach of familial hypercholesterolemia and indications to HELP therapy.
Keywords: Familial hypercholesterolemia, atherosclerosis, hydroxymethylglutaryl, CoA Reductase Inhibitors, Lipoproteins LDL apheresis

CITATION

Gaipov A, Abseitova S, Malykh D. Extracorporeal removal of LDL in the treatment of familial hypercholesterolemia. Journal of Clinical Medicine of Kazakhstan. 2015;2(36):15-22.

REFERENCES

  • Varghese MJ. Familial hypercholesterolemia: A review, Ann Pediatr Cardiol, 2014, No.7(2), pp.107-117.
  • Narverud I, Retterstol K, Iversen PO, Halvorsen B, Ueland T, Ulven SM, et al. Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review, Atherosclerosis, 2014, No.235(2), pp.299-309.
  • Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J, 2011, No.32(14), pp.1769-1818.
  • Singh S, Bittner V. Familial hypercholesterolemia--epidemiology, diagnosis, and screening, Curr Atheroscler Rep, 2015, No.17(2), p.482.
  • Shi Z, Yuan B, Zhao D, Taylor AW, Lin J, Watts GF. Familial hypercholesterolemia in China: prevalence and evidence of underdetection and undertreatment in a community population, Int J Cardiol, 2014, No.174(3), pp.834-836.
  • Nanchen D, Gencer B, Auer R, Raber L, Stefanini GG, Klingenberg R, et al. Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes, Eur Heart J, 2015, No. 4.
  • De Backer G, Besseling J, Chapman J, Hovingh GK, Kastelein JJ, Kotseva K, et al. Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology, Atherosclerosis, 2015, No.241(1), pp.169-175.
  • Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study, BMJ, 2001, 28, No.322(7293), pp.1019-1023.
  • Seguro F, Bongard V, Berard E, Taraszkiewicz D, Ruidavets JB, Ferrieres J. Dutch Lipid Clinic Network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population, Arch Cardiovasc Dis, 2015, No.11.
  • Dann EJ, Shamir R, Mashiach T, Shaoul R, Badian A, Stravets T, et al. Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis, Transfus Apher Sci, 2013, No.49(2), pp268-277.
  • Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue, J Clin Apher, 2013, No.28(3), pp.145-284.
  • Choluj B, Votruba T, Kormuth E. Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atheroslcerosis. Part I: Principles of classification and methods of dyslipoproteinemia determination, Acta Univ Carol Med (Praha), 1991, No.37(3-4), pp.91-105.
  • Kwiterovich PO, Jr. Dyslipoproteinemia and other risk factors for atherosclerosis in children and adolescents, Atherosclerosis, 1994, No.108 (Suppl), pp.55-71.
  • Bajkov A, Kanskaja N, Pozdnjakova I. Dislipoproteinemija i disproteinemija pri boleznjah serdca (Dislipoproteinemia and Dysproteinemia for heart disease), International Journal, 2010, No.12(2), p.145.
  • Stone MC, Thorp JM, Mills GL, Dick TB. Diagnosis and classification of abnormal lipoprotein patterns, Clin Chim Acta, 1971, No.31(2), pp.333-354.
  • Vogt HB. Hyperlipoproteinemias: Part I. Lipoprotein classification and abnormalities, S D J Med, 1991, No.44(2), pp.43-46.
  • Niedbala RS, Schray KJ, Foery R, Clement G. Estimation of low-density lipoprotein by the Friedewald formula and by electrophoresis compared, Clin Chem, 1985, No.31(10), pp.1762-1763.
  • Kapoor R, Chakraborty M, Singh N. A Leap above Friedewald Formula for Calculation of Low-Density LipoproteinCholesterol, J Lab Physicians, 2015, No.7(1), pp.11-16.
  • Youngblom E, Knowles JW. Familial Hypercholesterolemia. 1993.
  • Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia, Nat Clin Pract Cardiovasc Med, 2007, No.4(4), pp.214-225.
  • Vuorio AF, Turtola H, Kontula K. Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent with a molecularly defined heterozygous familial hypercholesterolemia, Arterioscler Thromb Vasc Biol,1997, No.17(11), pp.3332- 3337.
  • Organization WH. Familial Hypercholesterolaemia (FH): report of a second WHO consultation, Geneva, 4 September 1998: World Health Organization, Human Genetics Program; 1999.
  • Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, et al. Guidelines for the management of familial hypercholesterolemia, J Atheroscler Thromb, 2012, No.19(12), pp.1043-1060.
  • Sjouke B, Hovingh KG, Kastelein JJ, Stefanutti C. Homozygous autosomal dominant hypercholesterolemia: prevalence, diagnosis, and current and future treatment perspectives, Curr Opin Lipidol, 2015, No. 16.
  • Allard D, Amsellem S, Abifadel M, Trillard M, Devillers M, Luc G, et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia, Hum Mutat, 2005, No.26(5), p.497.
  • Najam O, Ray KK. Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management, Cardiol Ther, 2015, No.4(1), pp.25-38.
  • Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review, JAMA, 2003, No.2;290(1), pp.86-97.
  • Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D. Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system, Klin Wochenschr, 1987, 16, No.65(4), pp.161-168.
  • Gaipov A, Nogaibayeva A, Zharmukhanbet L, Orazbayev G, Malykh D, Popova N, et al., editors. Short-term Effect Of LDLApheresis On Lipid Profile Of Patients With Nephrotic Syndrome And Coronary Artery Disease: A Comparative Data. World Congress of Nephrology 2015, 13-17 March, Cape Town, South Africa; 2015.
  • Tuganbekova SK, Gajpov AJe. Jekstrakorporal’noe udalenie lipidov nizkoj plotnosti (Extracorporeal removal of low density lipid). Klinicheskij protokol operativnogo i diagnosticheskogo vmeshatel’stva, protokol №6. Astana: «Respublikanskij centr razvitija zdravoohranenija» Ministerstva zdravoohranenija i social’nogo razvitija Respubliki Kazahstan ot 12 dekabrja, 2014. p. 10.